Insulet reported a 29.9% year-over-year revenue increase in its most recent quarter, driven by accelerating adoption of its tubeless Omnipod 5 insulin pump system. The company achieved revenue of $521.7 million, with consumable Pod sales accounting for over two-thirds of that figure. Gross margins expanded by 240 basis points sequentially, reflecting improved manufacturing efficiencies as unit volumes rose by more than 35% compared with the prior year. Management expects margins to continue scaling as Omnipod 5 production ramps and new manufacturing capacity comes online in early 2025.

During the third quarter, Braun Stacey Associates initiated a position of 53,952 Insulet shares valued at approximately $16.7 million. Other major investors also increased their stakes: Vanguard added 39,403 shares in the second quarter, lifting its holdings to 8.7 million shares; Geode Capital purchased 58,309 shares to bring its total to 1.93 million; and Federated Hermes raised its position by 14.3%, or 90,494 shares, reaching 723,363 shares. Norges Bank entered with a new holding valued at $324.7 million, underscoring growing institutional conviction in Insulet’s growth trajectory.

Insulet posted adjusted EPS of $1.24, beating consensus by $0.11 and reflecting a 14.8% increase from $1.08 a year earlier. Net margin improved to 9.76%, up from 8.2% in the prior-year period. Despite revenue coming in below some Wall Street projections, analysts have raised their 12-month price targets and earnings estimates. Raymond James elevated its target to $385 and maintained an “outperform” rating, while JPMorgan raised its objective to $415 with an “overweight” stance. Consensus forecasts now call for full-year EPS of $3.92, up from $3.60 at the start of the year.

Concentration risk remains a consideration, as Omnipod 5 generates over 70% of total sales and faces competition from both established pump makers and emerging CGM-integrated systems. Foreign exchange headwinds could pressure margins if the U.S. dollar strengthens, given that roughly 40% of Insulet’s revenue is international. Management reiterated its long-term targets of mid-20% revenue growth and high-single-digit operating margin expansion, but emphasized that achieving those goals depends on successful new product introductions and continued supply-chain stability.